RAD52 S346X was highly significantly associated with reduced risk of breast cancer for BRCA2 carriers (Table 1 and Table S1); each copy of the minor allele was estimated to confer a per‐allele HR of 0.69 (95% CI, 0.56 to 0.86, P = 0.0008). Here, RAD52 is linked to breast carcinoma.